Prevalence of Anti-JC Virus Antibody in Multiple Sclerosis Patients in Kuwait

S. Lamdhade, A. Ashkanani, and R. Alroughani

1 Division of Neurology, Department of Medicine, Amiri Hospital, Arabian Gulf Street, 13041 Kuwait City, Kuwait
2 Neurology Clinic, Dasman Diabetes Institute, P.O. Box 1180, 15462 Dasman, Kuwait

Correspondence should be addressed to R. Alroughani; alroughani@gmail.com

Received 3 October 2013; Accepted 20 November 2013; Published 22 January 2014

Copyright © 2014 S. Lamdhade et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Background. Multiple sclerosis (MS) therapeutics entered a new era after the development of anti-JC virus (anti-JCV) antibody assay that assesses the risk of development of progressive multifocal leukoencephalopathy (PML) in patients treated with natalizumab.

Objective. To determine the prevalence of anti-JCV antibody among MS patients in Kuwait.

Methods. Using the national MS registry, demographics and disease characteristics of MS patients who were screened for anti-JCV antibody were collected. The prevalence of anti-JCV antibody seropositivity and its association with demographic and disease characteristics were evaluated.

Results. Out of 110 screened MS patients for anti-JCV antibodies, 65.5% were females. Mean age and disease duration were 29.23 ± 8.55 and 5.39 ± 5.04 years, respectively. 47.3% of patients were already on natalizumab and 52.7% of patients were screened for stratification to either natalizumab or a different Disease Modifying Therapy (DMT). The overall prevalence of anti-JCV virus antibody was 40%. Gender (P = 0.69), disease duration (P = 0.11), and number of natalizumab infusions (P = 0.64) were not associated with seropositivity. Patients aged ≥30 years were more likely to be seropositive (P = 0.01).

Conclusion. The prevalence of anti-JCV antibody is slightly lower than what is reported in published studies. Seropositivity was associated with an increasing age of MS patients.

1. Introduction

Progressive multifocal leukoencephalopathy (PML) is a rare neurological disease, which is caused by JC virus (JCV) infection. Reactivation of JCV occurs usually in immunocompromised or AIDS patients. JCV infection has gained importance to neurologists after the report of two PML cases in multiple sclerosis (MS) patients who received natalizumab [1].

The tremendous advances in the understanding of MS pathology and pharmacotherapy have improved the patients’ outcomes significantly. Given the concern of PML, the benefit of natalizumab treatment is to be weighed against its risk. After the recent development of blood anti-JC virus antibody test, stratification of MS patients to various disease modifying therapies (DMTs) entered a new era [2]. Hence, studying the prevalence of JCV in MS patients became important, as it would impact the clinical decision-making, especially in patients who had received prior immunosuppressants or are receiving natalizumab for more than 24 months. Although many cases of PML have been reported from various parts of the globe, the relationship between the number of natalizumab infusions and risk of PML development has not been clearly established yet [3].

Few studies indicated that approximately 60–70% of MS patients were seropositive when screened for anti-JCV antibody [4]. Most of the available data come from North America and Europe. We have studied the prevalence of anti-JC virus antibody in Kuwait, which represents one of the highest regions of Middle East affected by MS [5].

2. Methods

We have retrospectively assessed the database of MS patients who were screened for anti-JCV antibody using the MS registry in two MS centers in Kuwait in the period between October 2012 and June 2013. Patients who were diagnosed with MS according to the revised 2010 McDonald criteria
Table 1: Clinical characteristics of cohort (n = 110).

| Characteristics                        | N, SD (%) |
|----------------------------------------|-----------|
| Mean age (years)                       | 29.23 ± 8.55 |
| Gender                                 |           |
| Female                                 | 72 (65.5%) |
| Male                                   | 38 (34.5%) |
| Mean disease duration (years)          | 5.39 ± 5.04 |
| MS course                              |           |
| Relapsing remitting                    | 98 (89.09%) |
| Secondary progressive                  | 12 (10.91%) |
| Mean EDSS score                        | 3.75 ± 1.45 |
| Current DMTs when tested               |           |
| None                                   | 11 (10%)  |
| IFN beta 1a IM                         | 18 (16.36%) |
| IFN beta 1a SC                         | 10 (9.09%) |
| IFN beta 1b SC                         | 13 (11.82%) |
| Fingolimod                             | 5 (4.55)  |
| Natalizumab                            | 52 (47.27%) |
| Others                                 | 1 (0.91%)  |

Table 2: Characteristics of anti-JCV antibody seropositive group (n = 44).

| Characteristics                        | N, SD (%) |
|----------------------------------------|-----------|
| Mean age (years)                       | 33 ± 7.84 |
| Gender                                 |           |
| Female                                 | 30 (68.2%) |
| Male                                   | 14 (31.8%) |
| Mean disease duration (years)          | 6.95 ± 6.67 |
| MS course                              |           |
| Relapsing remitting                    | 38 (83.4%) |
| Secondary progressive                  | 6 (13.6%)  |
| Mean EDSS score                        | 3.88 ± 1.53 |
| Current DMTs when tested               |           |
| None                                   | 4 (9.1%)   |
| Other DMTs except natalizumab          | 23 (52.2%) |
| Natalizumab                            | 17 (38.6%) |

Table 3: Analysis of the status of anti-JCV antibody according to prespecified demographics and disease characteristics.

| Variables                        | Anti-JCV antibody status | P value |
|----------------------------------|--------------------------|---------|
|                                  | Negative | Positive |         |
| Gender                           |           |          |         |
| Female                           | 42        | 30       | 0.69    |
| Male                             | 24        | 14       |         |
| Mean age ≥30 years               |           |          |         |
| <30 years                        | 36        | 13       | 0.02*   |
| ≥30 years                        | 30        | 31       | 0.01*   |
| Mean disease duration (years)    |           |          |         |
| <30 years                        | 5.39 ± 4.52 | 6.95 ± 5.66 | 0.11 |
| ≥30 years                        | 3.67 ± 1.41 | 3.88 ± 1.53 | 0.28 |

*Statistically significant.

3. Results

Of 110 screened MS patients for anti-JCV virus antibodies, 72 (65.5%) were females. Patients’ demographics, clinical characteristics, and their current medications were listed in Table 1. The mean age and disease durations were 29.23 ± 8.55 years and 5.39 ± 5.04 years, respectively. Most of the patients (89.09%) had relapsing remitting MS and the mean EDSS score of the studied cohort was 3.75 ± 1.45 as shown in Table 1. The indication for screening was either to test patients who were already on natalizumab (47.3%, n = 52) or to stratify patients to be treated with either natalizumab or other disease modifying therapy (52.7%, n = 68).

The overall prevalence of seropositivity to anti-JCV virus antibody was 40% (n = 44), of whom 68.2% were females. The characteristics of seropositive patients are shown in Table 2. Clinical parameters such as gender (P = 0.69), disease duration (P = 0.11), and the number of natalizumab infusions (P = 0.64) were not associated with seropositivity. Patients aged ≥30 years were more likely to be seropositive (P = 0.011) as outlined in Table 3.

After the results of anti-JCV antibody in patients who were not on natalizumab, 7 seropositive patients were prescribed natalizumab while 15 and 3 seropositive patients were prescribed fingolimod and interferons, respectively. Among seropositive patients who were tested while on natalizumab, 9 patients had subsequently stopped natalizumab (mean infusions 20; range 12–26) while 10 patients continued natalizumab (mean infusions 16.9; range 8–33). The mean infusion was 17.63 ± 10.48 for all patients who continued natalizumab irrespective of anti-JCV serostatus. There was no association between prior exposure to DMTs and anti-JCV antibody seropositivity in patients who were already on natalizumab.
Similar to other studies, the seropositivity increased with the age in our cohort. The mean age was higher in seropositive group (33.0 versus 29.2 years; \( P = 0.023 \)). Higher seropositive in men was common but not universally seen which could be due to higher age at onset in men [1, 3]. Gender did not seem to influence our results despite the observed non-significant predominant seropositivity in females (68.18%). Similarly, other studies did not find any significant gender difference [13, 14], suggesting that a larger sample size might be needed to better assess the gender difference.

A recent multinational study suggested that prior DMD was not an important factor for higher rates of seropositivity [4]. Similarly, Miller et al. did not find any correlation when first-line DMTs were used prior to the screening test in 239 patients [15]. Furthermore, there was no specific pattern between the type or the duration of prior immunosuppressant therapy and anti-JCV antibody seropositivity [16].

As far as number of natalizumab infusions was concerned, Bozic et al. did not find an increase in seropositivity when assessing 12-month increment of infusions [2]. In a study using JCV DNA in plasma with a mean infusion of 22 months, no significant correlation was observed with the number of natalizumab infusions [17].

Our study had several limitations. First, it included small number of patients, yet it represented the first regional cohort that would help in establishing a registry of anti-JCV antibody in the region. Second, there was a referral bias since most of the referrals to our MS centers were young MS patients with short disease duration. This could have impacted the overall prevalence of anti-JCV since age was a significant independent factor. Larger longitudinal studies are needed to clarify the interplay of multiple putative risk factors for proper risk stratification of PML.

In summary, the prevalence of anti-JCV antibody in MS cohort in Kuwait was 40%. This was slightly lower than European and North American data. Except for increasing age, we did not find any significant correlations between the presence of seropositive anti-JCV antibody and gender, prior first-line or immunosuppressant exposure, or number of natalizumab infusions. Although our cohort represents the first report from the Middle East, it underscores the urgent need of population-based seroprevalence determination in both healthy and MS cohorts.

**Conflict of Interests**

The authors declare that there is no conflict of interests regarding the publication of this paper.

**References**

[1] T. A. Yousry, E. O. Major, C. Ryschkewitsch et al., “Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy,” The New England Journal of Medicine, vol. 354, no. 9, pp. 924–933, 2006.

[2] C. Bozic, S. Richman, T. Plavina et al., “Anti-John Cunnigham virus antibody prevalence in multiple sclerosis patients: baseline results of STRATIFY-1,” Annals of Neurology, vol. 70, no. 5, pp. 742–750, 2011.
[3] A. K. Trampe, C. Hemmelmann, A. Stroet et al., “Anti-JC virus antibodies in a large German natalizumab-treated multiple sclerosis cohort,” *Neurology*, vol. 78, pp. 1736–1742, 2012.

[4] T. Olsson, A. Achiron, L. Alfredsson et al., “Anti-JC virus antibody prevalence in a multinational multiple sclerosis cohort,” *Multiple Sclerosis*, vol. 19, no. 11, pp. 1533–1538, 2013.

[5] R. Afroughani, S. Ahmed, R. Behbahani et al., “Increasing prevalence and incidence rates of multiple 5 sclerosis in Kuwait,” *Multiple Sclerosis*, 2013.

[6] C. H. Polman, S. C. Reingold, B. Banwell et al., “Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria,” *Annals of Neurology*, vol. 69, no. 2, pp. 292–302, 2011.

[7] P. Lee, T. Plavina, A. Castro et al., “A second-generation ELISA (STRATIFY JCV DxSelect) for detection of JC virus antibodies in human serum and plasma to support progressive multifocal leukoencephalopathy risk stratification,” *Journal of Clinical Virology*, vol. 57, pp. 141–146, 2013.

[8] A. Egli, L. Infanti, A. Dumoulin et al., “Prevalence of polyomavirus BK and JC infection and replication in 400 healthy blood donors,” *Journal of Infectious Diseases*, vol. 199, no. 6, pp. 837–846, 2009.

[9] A. Antonsson, A. C. Green, K.-A. Mallitt et al., “Prevalence and stability of antibodies to the BK and JC polyomaviruses: a long-term longitudinal study of Australians,” *Journal of General Virology*, vol. 91, no. 7, pp. 1849–1853, 2010.

[10] K. Khalili, M. K. White, F. Lublin, P. Ferrante, and J. R. Berger, “Reactivation of JC virus and development of PML in patients with multiple sclerosis,” *Neurology*, vol. 68, no. 13, pp. 985–990, 2007.

[11] A. Sandrock, C. Hotermans, S. Richman et al., “Risk stratification for progressive multifocal leukoencephalopathy (PML) in MS patients: role of prior immunosuppressant use, natalizumab-treatment duration, and anti-JCV antibody status,” American Academy of Neurology, Poster 03.248, 2011.

[12] L. Gorelik, M. Lerner, S. Bixler et al., “Anti-JC virus antibodies: implications for PML risk stratification,” *Annals of Neurology*, vol. 68, no. 3, pp. 295–303, 2010.

[13] C. Warnke, T. Dehmel, A. Posevitz-Fejfar et al., “Anti-JC-virus antibody prevalence in a German MS cohort,” *Multiple Sclerosis*, vol. 18, pp. 1054–1055, 2012.

[14] A. Achiron, J. Chapman, M. Dolev et al., “Epidemiology of anti-JCV antibodies in israeli multiple sclerosis population (P02.138),” *Neurology*, vol. 78, P02.138, 2012.

[15] C. S. Miller, S. A. Houff, J. Hopper et al., “Disease-modifying drugs for multiple sclerosis and JC virus expression,” *Journal of NeuroVirology*, vol. 18, pp. 411–415, 2012.

[16] P. S. Sørensen, A. Bertolotto, G. Edan et al., “Risk stratification for progressive multifocal leukoencephalopathy in patients treated with natalizumab,” *Multiple Sclerosis*, vol. 18, no. 2, pp. 143–152, 2012.

[17] R. A. Rudick, P. W. O’Connor, C. H. Polman et al., “Assessment of JC virus DNA in blood and urine from natalizumab-treated patients,” *Annals of Neurology*, vol. 68, no. 3, pp. 304–310, 2010.